JMP Securities Downgrades BioCryst Pharma (BCRX) to Market Perform
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.31 --0%
Rating Summary:
18 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 22
Rating Summary:
18 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 22
Join SI Premium – FREE
JMP Securities downgraded BioCryst Pharma (NASDAQ: BCRX) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $1.48 yesterday.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $1.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Principal Financial Group (PFG) to Underperform
- JPMorgan Downgrades Wipro Ltd. (WIT) to Underweight
- Axis Capital Limited Downgrades Tech Mahindra Ltd. (TECHM:IN) to Sell (4)
Create E-mail Alert Related Categories
DowngradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
